| Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute … T Badar, HM Kantarjian, F Ravandi, E Jabbour, G Borthakur, JE Cortes, ... Leukemia research 39 (9), 950-956, 2015 | 90 | 2015 |
| Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes T Badar, KP Patel, PA Thompson, C DiNardo, K Takahashi, M Cabrero, ... Leukemia research 39 (12), 1367-1374, 2015 | 62 | 2015 |
| Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma RW Merryman, L Castagna, L Giordano, VT Ho, P Corradini, A Guidetti, ... Leukemia 35 (9), 2672-2683, 2021 | 58 | 2021 |
| Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia T Badar, DR Handisides, JM Benito, MA Richie, G Borthakur, E Jabbour, ... American journal of hematology 91 (8), 800-805, 2016 | 37 | 2016 |
| Bone marrow necrosis in acute leukemia: clinical characteristic and outcome T Badar, A Shetty, C Bueso‐Ramos, J Cortes, M Konopleva, G Borthakur, ... American journal of hematology 90 (9), 769-773, 2015 | 37 | 2015 |
| Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia A Zahrani, M Kandil, T Badar, M Abdelsalam, A Al-Faiar, A Ismail Tumori Journal 100 (1), 75-79, 2014 | 35 | 2014 |
| Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms HB Alkhateeb, A Nanaa, D Viswanatha, JM Foran, T Badar, L Sproat, ... Blood advances 6 (2), 528-532, 2022 | 33 | 2022 |
| Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies T Badar, JE Cortes, F Ravandi, S O'Brien, S Verstovsek, G Garcia-Manero, ... Clinical Lymphoma Myeloma and Leukemia 15 (7), 433-438. e2, 2015 | 32 | 2015 |
| Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab T Badar, A Szabo, A Advani, M Wadleigh, S Arslan, MA Khan, I Aldoss, ... Blood Advances 4 (10), 2308-2316, 2020 | 29 | 2020 |
| Postrelapse survival in diffuse large B-cell lymphoma after therapy failure following autologous transplantation N Epperla, T Badar, A Szabo, J Vaughn, S Borson, NY Saini, RD Patel, ... Blood advances 3 (11), 1661-1669, 2019 | 29 | 2019 |
| Higher prevalence of KRAS mutations in colorectal cancer in Saudi Arabia: Propensity for lung metastasis T Badar, A Ismail Alexandria Journal of Medicine 50 (3), 203-209, 2014 | 28 | 2014 |
| Outcomes of TP53 mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival MD Patel, Y Abaza, JP Bewersdorf, AN Saliba, GSDC Correia, A Duvall, ... | 27 | 2022 |
| Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy DA Bond, JM Switchenko, D Villa, K Maddocks, M Churnetski, AS Gerrie, ... Blood advances 5 (23), 5179-5189, 2021 | 24 | 2021 |
| Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade T Badar, HM Kantarjian, GM Nogueras‐Gonzalez, G Borthakur, ... American journal of hematology 90 (11), 1065-1070, 2015 | 24 | 2015 |
| Safety and feasability of Muslim fasting while receiving chemotherapy T Badar, A Ismail, A AlShanqeeti IOSR Journal of Pharmacy 4, 15-20, 2014 | 24 | 2014 |
| Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes T Badar, A Szabo, D Sallman, R Komrojki, J Lancet, E Padron, J Song, ... Leukemia & lymphoma 61 (6), 1418-1427, 2020 | 23 | 2020 |
| Ibrutinib: a paradigm shift in management of CLL T Badar, JA Burger, WG Wierda, S O’Brien Expert review of hematology 7 (6), 705-717, 2014 | 22 | 2014 |
| Chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia T Badar, NN Shah Current Treatment Options in Oncology 21, 1-11, 2020 | 20 | 2020 |
| Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT T Badar, N Epperla, A Szabo, S Borson, J Vaughn, G George, N Saini, ... Blood Advances 4 (1), 47-54, 2020 | 20 | 2020 |
| Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second … T Badar, A Szabo, S Dinner, M Liedtke, M Burkart, RM Shallis, ... Cancer 127 (7), 1039-1048, 2021 | 18 | 2021 |
Jorge CortesGeorgia Cancer CenterE-mail confirmado em augusta.edu
